PURPOSE. Tetramethylpyrazine (TMP) is the active ingredient extracted from the Chinese herb Chuanxiong. The purpose of our study was to identify the mechanism of therapeutic TMP suppression of pathologic chemokine receptor 4 (CXCR4) transcription.
C orneal neovascularization (CNV) obscures the corneal transparency essential for optimal vision. 1 New blood vessels usually occur in response to alkali burns, keratitis, trauma, and keratoplasty, which can all damage vision and even cause blindness. 2 CNV arises from the pre-existing vasculature that surrounds the cornea. During neovascularization, new vessels invade and grow in the normally avascular cornea, severely impairing vision. 3, 4 CNV is fostered by a variety of angiogenic factors, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor, and chemokine receptor 4 (CXCR4). [5] [6] [7] [8] [9] [10] Our previous studies showed that tetramethylpyrazine (TMP) inhibits CNV by downregulating CXCR4 expression. 10 Chuanxiong is an herb that, for over 2000 years, has been used in traditional Chinese medicine to treat a variety of diseases. The active component, TMP, shows strong antiangiogenic properties, and neuroprotective and antitumor effects, both in vitro and in vivo. [11] [12] [13] This herbal supplement remarkably promotes microcirculation and improves blood flow by attenuating thrombus formation, decreasing blood viscosity, dissipating blood stasis, and dilating blood vessels, and thus is an effective therapy for numerous cardiovascular and cerebrovascular diseases. 10 TMP was recently proven to inhibit neovascularization in ophthalmologic diseases, with mild side effects.
14 Early investigations revealed TMP decreases CNV and inhibits neovascularization in ischemic retinas, but the mechanisms of TMP's antiangiogenic effects have remained unclear.
Our previous study suggested TMP might attenuate CNV by targeting CXCR4, which is linked to vascular formation. Although CXCR4 expression is regulated by various transcriptional factors in different processes, those targeted by TMP remained unknown.
CXCR4 is a 7-transmembrane domain, G-protein-coupled receptor, expressed in a variety of cells, including vascular endothelial cells, neurons, and cancer cells. [15] [16] [17] [18] [19] Its normal functions appear to be diverted, causing it to drive neovascularization of various diseases, such as pathologic neovascularization, myocardial infarction, cancer, and inflammation. sion, including nuclear factor kappa B (NFjB), 23 nuclear respiratory factor-1 (NRF-1), 24 forkhead box C1 (FoxC1), 25 and yin yang 1 (YY1). 26 The transcription factor YY1 was reported to bind the CXCR4 promoter during breast cancer progression and metastasis and during human herpes virus 6 infection; 27, 28 and YY1, along with CXCR4, intervenes in the pathogenesis of osteosarcoma on cell invasiveness. 29 In addition, Foxc1 activation of CXCR4 expression controls mesenchyme differentiation and chemotactic motility of endothelial cells. 30 Previously, we showed NRF-1 regulates CXCR4 transcription in the rat retina. 31 Because NRF-1 reportedly activates the CXCR4 promoter during entry of the human immunodeficiency virus type 1, 32 and NFjB is upregulated in retinal vein occlusion and patients with diabetic retinopathy, 33 these two proteins seemed like likely potential targets of therapeutic TMP treatment for CNV.
Our studies in vivo, in alkali burn-injured mice, confirm TMP inhibits CNV by downregulating expression of CXCR4, NFjB, and NRF-1. Moreover, our chromatin immunoprecipitation (ChIP) and genetic interference assays show NRF-1 binds the CXCR4 promoter directly, and TMP treatment decreased this binding efficiency in vitro. Additionally, NFjB interacted with CXCR4 indirectly by regulating NRF-1 expression and repressing downstream-target gene expression. Thus, the use of TMP to target NRF-1 and NFjB may have therapeutic potential as a treatment for CNV disorders.
MATERIALS AND METHODS

Cell Culture
The human umbilical vein endothelial cell (HUVEC) line was obtained from the ATCC Collection (Manassas, VA, USA) and grown in Dulbecco's modified Eagle's medium (Invitrogen, Grand Island, NY, USA) supplemented with 10% fetal bovine serum in humidified conditions of 5% carbon dioxide at 378C. The HUVEC line used in experiments was the same batch at different passages. TMP applied to cells was purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA) and dissolved in a component solvent (saline:dimethyl sulfoxide 1:1) to reach a concentration of 200 lmol/L. The same amount of component solvent was used as a control in all cell experiments accordingly.
Animals and Model of Corneal Alkali Burn
A total of 80 C57BL/6J mice aged 6 to 8 weeks were purchased from the Guangdong Provincial Center for Animal Research (Guangzhou, China). Their right eyes were selected for experimentation. After anesthetized with an intraperitoneal injection of 4.3% chloral hydrate (400 mg/kg; Sigma-Aldrich Corp.), the mice were administrated topical anesthesia with a drop of tetracaine on their corneal surfaces. Alkali burn injury was induced by placing a 2-mm-diameter filter paper soaked with 1 M NaOH on the central cornea for 40 seconds, with help of a surgical microscope. Then, the eyes were gently flushed with a 0.9% saline solution for 120 seconds. TMP (Harbin Medisan Pharmaceutical Co., Haerbin, China) was diluted in a 0.9% saline solution at the concentration of 1.5 mg/ mL. The mice were assigned to 2 groups (n ¼ 40) randomly. One group consisted of mice treated with normal saline treatment after alkali injury, and the other group consisted of mice treated with TMP treatment (1.5 mg/mL; 4 times daily) after alkali injury. On day 3 after injury, RNA of murine corneas was extracted for real-time PCR analysis. On day 14 after injury, CNV of mice was evaluated by slit lamp microscopy (Zeiss, Inc., Jena, Germany), and then mice were sacrificed for immunohistochemistry and immunofluorescence staining.
Evaluation of CNV
With the help of slit lamp microscopy, CNV was observed and clinical assessment was performed according to a scoring system. Corneal opacity was scored on a scale of 0 to 4 and neovessel size was scored on a scale of 0 to 3, according to an existing standard. 34 Two independent observers marked the score, and the final score was the average of the two. Photographs were snapped at 7 days after TMP treatment by slip lamp microscopy.
After photographed with the slit lamp microscopy, freshly enucleated murine eyes were prepared into flattened corneal tissue. 35 CNV was stained with FITC-conjugated CD31/PECAM-1 (rat anti-mouse antibody; BD Pharmingen, San Jose, CA, USA). Stained corneas were observed under a fluorescence microscope (BX50; Olympus, Tokyo, Japan) at 203 magnification. Image J software was used to calculate the area of neovascularization on the basis of immunohistochemic staining results.
Immunofluorescence Staining
On day 7 after injury, the whole eyes were removed from mice and sliced at 10 lm by using a Leica microtome (Bannockburn, IL, USA). After drying, sections were stained with 4 0 ,6-diamidino-2-phenylindole (DAPI), VEGF, NRF-1, CXCR4, and NFjB and then photographed.
HUVECs were fixed with 4% paraformaldehyde for 15 minutes, and subsequently treated with 10% goat serum for 30 minutes. Cells were incubated with primary antibodies against CXCR4 (1:100; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), NRF-1 (1:100; Abcam, Cambridge, MA, USA), and NFjB (Boster, Wuhan, China) overnight at 48C. Secondary anti-mouse or anti-goat antibody (1:500 dilution, Cell Signaling Technology, Danvers, MA, USA) was added at room temperature, and DAPI was used to stain nuclei. Photomicrographs were captured by fluorescence system.
Real-Time RT-PCR
Expression of CXCR4, NRF-1, NFjB, YY1, and FoxC1 was measured after TMP treatment by real-time PCR analyses by using the SYBR Green system (Takara, Tokyo, Japan). The following primer pairs were used: for b-actin, 
Western Blotting
Cells were lysed using radio-immunoprecipitation assay buffer, and protein was extracted at 48C. CXCR4, NRF-1, and NFjB were detected using the primary antibodies rabbit anti-CXCR4 (1:200; Boster), rabbit anti-NRF-1 (1:1000; Abcam), and rabbit anti-NFjB (1:1000; Cell Signaling Technology) respectively. The nitrocellulose membrane was incubated with secondary anti-rabbit antibody (Cell Signaling Technology). Glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH; 1:5000; Proteintech, Rosemont, IL, USA) served as a loading control.
Cell Viability Assays by MTT
The viability of HUVECs was detected using the MTT assay 24 and 48 hours after TMP treatment. With 100 ll of dimethyl sulfoxide added to each well in 96-well plates, cells were incubated at 378C for 4 hours. Absorbance was measured at 490 nm with a fluorescence plate reader (Power Wave XS; BioTek, Winooski, VT, USA). Cell viability was determined using the optical density ratio of a treated culture relative to an untreated control.
Chromatin Immunoprecipitation (ChIP) Assay
After treated with 200 lmol/L TMP, HUVECs were subjected to a ChIP assay, according to the manufacturer's instructions using the ChIP assay kit (Upstate Cell Signaling Solutions, Lake Placid, NY, USA). The antibodies NRF-1 (Abcam), NFjB (Cell Signaling Technology), or normal IgG (Sigma-Aldrich Corp.) were used. DNA was purified by phenol/chloroform extraction and ethanol precipitation and amplified by PCR by using primers spanning the activated transcription factor site of the CXCR4 promoter (forward, 5
Plasmid Construction
The plasmid pEPI-NRF-1 was derived from pEPI-GFP (generously provided by H.J. Lipps); NRF-1 cDNA was inserted in pEPI-GFP by restriction-digested sites EcoRI and BamHI. The plasmid pEV-p105-NFjB was bought from Addgene (Cambridge, MA, USA). 
Ethics Statement
RESULTS
CNV Induced by Alkali Burn was Inhibited by TMP Treatment In Vivo
Because CNV peaks 2 weeks after injury, we measured the area of neovascularization at that time. At day 14, mice subjected to TMP treatment or PBS treatment were anaesthetized and photographed by slit lamp (Fig. 1B, 1C) , showing neovascularization (Fig. 1B) invaded the central cornea, staining robustly in the PBS-treated group. Comparatively, the TMP-treated group developed only modest neovascularization that was mainly restricted to the cornea periphery (Fig. 1C) . According to corneal flat-mounts stained with anti-CD31-fluorescent antibody, the area of neovascularization in the TMP-treated group was significantly smaller than that in the injury group (Fig. 1E, 1F ). Staining was examined under magnification (Fig.  1H, 1I) , showing neovascularization in the injury group was denser and longer than in the TMP-treated group. In the TMPtreated group, the relative degree of CNV was significantly lower than that of the injury group (43.29% and 23.70%, respectively) (Fig. 1J) . The murine corneas were examined with a surgical microscope and scored according to the observed degree of edema, corneal opacity, area of neovascularization, and vessel size, with scores reflecting the severity of injury. By these criteria, the average score of the TMP-treated group was significantly lower than the PBS-treated group (8.833 and 4.454, respectively) (Fig. 1K) .
Real-time PCR showed injury-triggered pathologic CXCR4 overexpression (12.41 6 7.87-fold) in the mouse cornea that could be repressed by TMP treatment (5.26 6 2.07-fold), strongly suggesting that TMP attenuates CNV by inhibiting CXCR4 expression (Fig. 1L) .
The Expression Levels of the NRF-1 and NFjB Transcription Factors Correlate With CXCR4 Expression
Depending on the biologic setting, various genes can regulate the CXCR4 promoter, including NRF-1, NFjB, FoxC1, and YY1, but it is not clear which factors might be the target(s) of TMPmediated CNV inhibition. To determine this, we measured the expression changes of NRF-1, NFjB, FoxC1, and YY1 at day 3 after injury. According to RT-PCR results, expression of both NRF-1 and NFjB was stimulated by injury but reduced by TMP treatment-changes that mirrored the trend of CXCR4 expression. As shown in Figure 2A , TMP treatment after injury downregulated NRF-1 expression compared to the untreated group (control, 1-fold; the injury group, 1.83 6 0.62-fold; the TMP-treated group, 0.71 6 0.23-fold). NFjB expression ran parallel to the trend of NRF-1 expression: injury upregulated NFjB but this could be ameliorated by TMP treatment ( Fig. 2B ; control, 1-fold; the injury group, 2.69 6 1.60-fold; the TMP treated group, 0.89 6 0.30-fold). In contrast, expression of FoxC1 and YY1 declined after injury, and the PBS-treated and TMP-treated groups showed no statistic difference in expression of FoxC1 and YY1 (Fig. 2C, 2D ). These results show TMP effectively downregulates CXCR4, NRF-1, and NFjB expression in murine corneas, suggesting NRF-1 and NFjB might be the transcription factors targeted by TMP during neovascularization inhibition.
CXCR4, NRF-1, and NFjB Expression Decreases In Vivo After TMP Treatment
Immunofluorescence staining at day 14 postinjury showed the corneas of the TMP-treated group were thinner than in the injury group, indicating significantly milder edema and stromal inflammation with TMP treatment. Because VEGF is wellknown to induce neovascularization in vivo, fluorescence intensity was compared among the 3 groups, showing strong VEGF expression in the corneal epithelium, especially in the cytoplasm after injury (Fig. 3A) . Treatment with TMP eye drops significantly reduced the intensity of VEGF fluorescence. The staining intensity of CXCR4 was also notably reduced in the TMP-treated group (Fig. 3B) . To explore what upstream changes might influence CXCR4 expression, murine corneas were also fluorescently stained for NRF-1. As shown in Figure   TMP Blocks NFjB/NRF-1/CXCR4 Axis IOVS j April 2018 j Vol. 59 j No. 5 j 2135 The groups without injury (Con), the group treated with PBS after injury (Injury), and the group treated with TMP were observed at day 3. n ¼ 9/group; *P < 0.05. The average scores of the TMP-treated group were significantly lower than the scores of the PBS-treated group. (L) CXCR4 mRNA expression in the uninjured group, the injured group treated with PBS, and the injured group treated with TMP, as detected by RT-PCR at day 3. CXCR4 expression increased after injury, as compared to the uninjured mice. CXCR4 expression was inhibited by TMP treatment at day 3. n ¼ 10/group; *P < 0.05, **P < 0.01.
3C, NRF-1 was primarily found in nuclei and rarely in the cytoplasm; and the NRF-1 staining intensity was much lower after TMP treatment. After alkali injury, nuclei in the corneal epithelium stained positive for NFjB, indicating that NFjB had translocated from the cytoplasm to the nuclei. With treatment by TMP eye drops, the staining intensity of NFjB was markedly weaker (Fig. 3D) . Thus, treatment of TMP attenuated corneal edema and inflammation and imposed an inhibitory effect on the expression of VEGF, CXCR4, NRF-1, and NFjB. 
Treatment Targets the Transcription Factors NRF-1 and NFjB In Vitro
To confirm the above results, expression of these genes was tracked in HUVECs with or without 200 lmol/L TMP treatment. Immunofluorescence staining showed that CXCR4 and NFjB were normally located in the cytoplasm, with NRF-1 mainly staining in nuclei (Fig. 4A) . At different timepoints after TMP treatment, HUVECs were extracted for real-time PCR and Western blot assays, which showed that CXCR4 mRNA was downregulated in a time-dependent manner after TMP treatment ( Fig. 4B ; for CXCR4: control [con], 1; 24 hours, 81.32% 6 9.75%; 48 hours, 56.25% 6 4.04%; for NRF-1: con, 1; 24 hours, 81.91% 6 11.22%; 48 hours, 77.26% 6 2.15%; for NFjB: con, 1; 24 hours, 84.43% 6 8.28%; 48 hours, 68.78% 6 3.37%). Treated cells were extracted for Western blot analysis, at the same timepoints, and the relative intensity of the bands (normalized to GAPDH) was quantified by densitometry and compared. Consistently, a decrease was observed at the posttranscriptional level (Fig. 4C, 4D ; for CXCR4: con, 1; 24 hours, 70.92% 6 0.43%; 48 hours, 38.52% 6 0.63%; for NRF-1: con, 1; 24 hours, 91.58% 6 2.50%; 48 hours, 67.16% 6 3.72%; for NFjB: con, 1; 24 hours, 93.11% 6 3.26%; 48 hours, 54.98 6 0.13%). These results supported the idea that TMP inhibited neovascularization by downregulating CXCR4, likely via inhibition of NRF-1 and NFjB. According to results of the MTT assay (Fig. 4E) , with the presence of 200 lmol/L TMP, the survival rate of HUVECs was reduced to 95.77% 6 1.03% at 24 hours and 93.34% 6 1.38% at 48 hours. Thus, TMP is clinically safe.
The Effects of NFjB and NRF-1 on CXCR4 Transcription In Vitro Are Not Synergistic
To confirm that NRF-1 and NFjB regulate the CXCR4 promoter, the transcription factors were expressed in HUVECs from recombinant transfection vectors (pEPI-NRF-1 and pEVp105-NFjB). Two days after transfection, cells were collected and expression of NRF-1, NFjB, and CXCR4 was evaluated by Western blotting assays, with GAPDH as a loading control. Here, in HUVECs overexpressing the recombinant NRF-1, CXCR4 expression was elevated ( Fig. 5A ; for NRF-1: con, 1-fold; þpEPI-NRF-1, 1.93 6 0.12-fold; for CXCR4: con, 1-fold; þpEPI-NRF-1, 2.14 6 0.41-fold). Similarly, the CXCR4 expression level increased with overexpression of NFjB ( Fig. 5C; for NFjB: con, 1-fold; þpEV-p105-NFjB, 1.15 6 0.06-fold; for CXCR4: con, 1-fold; þpEPI-NRF-1, 1.78 6 0.36-fold). Consistent with our experimental results in vitro, overexpression of both transcription factors had a not-quite-additive effect on CXCR4 expression, with the fold elevation in CXCR4 transcription in the presence of both (at 2.69 6 0.78-fold elevation) being less than the sum of the fold elevation of NRF-1 (2.14 6 0.41-fold) and NFjB plasmid (1.78 6 0.36-fold) ( Fig. 5E, 5F ; for NRF-1: con, 1-fold; þpEPI-NRF-1and pEV-p105-NFjB: 1.20 6 0.10-fold; for NFjB: con, 1-fold; þpEPI-NRF-1and pEV-p105-NFjB, 2.11 6 0.02-fold; for CXCR4: þvector, 1-fold; þpEPI-NRF-1 and pEVp105-NFjB, 2.69 6 0.78-fold).
NRF-1 Directly Activates CXCR4 Transcription, and NFjB Increases NRF-1 Expression In Vitro
The promoters bound by NRF-1 and NFjB in HUVECs were analyzed by ChIP at 48 hours after TMP treatment. As shown in Figure 6A , DNA was sonicated to fragments of~0.4 kb in length. After precipitated with rabbit antibodies to normal rabbit IgG (or NFjB and NRF-1), DNA was extracted for PCR or real-time PCR amplification using CXCR4 primers of 145 bp. In both control and TMP-treated HUVECs, the NRF-1 antibody immunoprecipitated DNA from which our CXCR4-promoterspecific primers robustly amplified a 145-bp product (Fig. 6B) , reflecting that NRF-1 binds the CXCR4 promoter directly. Realtime PCR compared CXCR4 expression in the control and TMP-treated groups, showing that the effect of NRF-1 on CXCR4 mRNA expression could be repressed by TMP treatment ( Fig. 6C; con, 1 ; the TMP treated group, 73.67% 6 9.49%). Surprisingly, however, ChIP analysis suggested NFjB does not bind the CXCR4 promoter (Fig. 6D) , implicating NRF-1, but not NFjB, as a direct transcriptional regulator of the CXCR4 promoter.
Because our results suggest that NFjB might influence CXCR4 expression indirectly, by regulating the NRF-1 promoter, we analyzed the effect of overexpressed, recombinant NFjB on the NRF-1 promoter (Fig. 6E, 6F ). As expected, recombinant NFjB overexpressed from a transfection vector induced stimulated NRF-1 expression, implicating NFjB as a regulator of NRF-1 in endothelial cells. 
DISCUSSION
In our mouse alkali-burn model of corneal injury, therapeutically applied TMP remarkably attenuated neovascularization by downregulating CXCR4 expression. Similarly, in our transcription assays in transfected cells, TMP blocked upregulation of NRF-1, NFjB, and CXCR4. Thus, our study suggests a mechanism for TMP's effect on CXCR4: TMP downregulates NFjB, which in turn prevents NFjB from pathologically overstimulating the NRF-1 to drive CXCR4 expression-a novel mechanism in which the NFjB/NRF-1/CXCR4 signaling pathway links TMP to inhibited neovascularization.
CXCR4 plays an important role in neovascularization and is regulated by various transcription factors in different processes or cell types. For example, YY1 binds the CXCR4 promoter during cancer invasiveness, progression, and metastasis 30, 32, 36 ; FoxC1 directly induces CXCR4 expression by activating its promoter in endothelial cells 33 ; and NRF-1 might be of critical importance in the proliferation of vascular smooth muscle cells (VSMCs) and during mitochondrial biogenesis in human vein endothelial cells. 37, 38 In the latter example, NFjB could promote VSMC proliferation and neointima formation, contributing to atherogenesis and progression of atherosclerotic plaque after arterial injury. [39] [40] [41] Such vascular inflammation and neovascularization might be attenuated by suppressing NFjB. 42, 43 In our study, CXCR4, NRF-1, and NFjB were prominently expressed in the epithelial layer of the murine cornea (Fig. 3) , and all of them were abnormally activated in parallel with alkali injury in vivo. TMP significantly downregulated the expression of CXCR4, NRF-1, and NFjB in parallel in CNV, making these transcription factors likely targets of therapeutic TMP for corneal injury.
Our data implicate NFjB as the target of therapeutic TMP, suggesting its effect on CXCR4 is indirect. TMP also protects endothelial cells from oxidative stress by downregulating NRF-1 expression. 44 This is likely relevant because repression of NFjB expression by TMP is anti-inflammatory in HUVECs and inhibits VSMC proliferation. 45, 46 Although NFjB does not directly bind the NRF-1 promoter (Fig. S1 ), supporting reports showed NFjB regulates the NRF-1 promoter, affecting downstream, target-gene expression. 47 By extension, these data support the idea that TMP inhibits CNV via the NFjB/NRF-1/ CXCR4 signaling pathway, which might be one of several, complex signaling pathways that respond to TMP in CNV. Going forward, other TMP targets will likely be uncovered by future studies, further supporting the modern clinical use of this ancient healing agent.
